相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Payer and Implementation Challenges with Advanced Therapy Medicinal Products (ATMPs)
John Spoors et al.
BIODRUGS (2021)
An overview of precision oncology basket and umbrella trials for clinicians
Jay J. H. Park et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Sponsorship and Funding for Gene Therapy Trials in the United States
Zachary Kassir et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
World Federation of Hemophilia Gene Therapy Registry
Barbara A. Konkle et al.
HAEMOPHILIA (2020)
Regenerative medicine regulatory policies: A systematic review and international comparison
Tingting Qiu et al.
HEALTH POLICY (2020)
Opportunities and challenges associated with the evaluation of chimeric antigen receptor T cells in real-life
Eoin McGrath et al.
CURRENT OPINION IN ONCOLOGY (2020)
Advanced therapy medicinal product manufacturing under the hospital exemption and other exemption pathways in seven European Union countries
Delphi G. M. Coppens et al.
CYTOTHERAPY (2020)
The New Normal in Clinical Trials: Decentralized Studies
E. Ray Dorsey et al.
ANNALS OF NEUROLOGY (2020)
Challenges and advantages of cell therapy manufacturing under Good Manufacturing Practices within the hospital setting
Emanuela M. Iancu et al.
CURRENT OPINION IN BIOTECHNOLOGY (2020)
Recalibrating Health Technology Assessment Methods for Cell and Gene Therapies
Aris Angelis et al.
PHARMACOECONOMICS (2020)
Manufacturing and Management of CAR T-Cell Therapy in COVID-19's Time: Central Versus Point of Care Proposals
Inaki Ortiz de Landazuri et al.
FRONTIERS IN IMMUNOLOGY (2020)
Patient and public perspectives on cell and gene therapies: a systematic review
Olalekan Lee Aiyegbusi et al.
NATURE COMMUNICATIONS (2020)
Barriers and Opportunities for Implementation of Outcome-Based Spread Payments for High-Cost, One-Shot Curative Therapies
Sissel Michelsen et al.
FRONTIERS IN PHARMACOLOGY (2020)
HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies
Doug Coyle et al.
EUROPEAN JOURNAL OF HEALTH ECONOMICS (2020)
Implementing managed entry agreements in practice: The Dutch reality check
A. Makady et al.
HEALTH POLICY (2019)
New clinical trial designs in the era of precision medicine
Elena Garralda et al.
MOLECULAR ONCOLOGY (2019)
The evolution of European HTA and access to innovative medicines
Kate Kolotourou et al.
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH (2019)
International collaborative actions and transparency to understand, diagnose, and develop therapies for rare diseases
Kym M. Boycott et al.
EMBO MOLECULAR MEDICINE (2019)
Are Payers Ready, Willing, and Able to Provide Access to New Durable Gene Therapies?
Jane F. Barlow et al.
VALUE IN HEALTH (2019)
The Genetically Modified Organism Medicinal Framework in Europe, United States, and Japan: Underlying Scientific Principles and Considerations Toward the Development of Gene Therapy and Genetically Modified Cell-Based Products
Houria Bachtarzi et al.
HUMAN GENE THERAPY CLINICAL DEVELOPMENT (2019)
Share and protect our health data: an evidence based approach to rare disease patients' perspectives on data sharing and data protection - quantitative survey and recommendations
Sandra Courbier et al.
ORPHANET JOURNAL OF RARE DISEASES (2019)
EU Regulatory Pathways for ATMPs: Standard, Accelerated and Adaptive Pathways to Marketing Authorisation
Giulia Detela et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2019)
Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors
Rachel Grosser et al.
CANCER CELL (2019)
A rare disease patient/caregiver perspective on fair pricing and access to gene-based therapies
Wendy White
GENE THERAPY (2019)
Hurdles of environmental risk assessment procedures for advanced therapy medicinal products: comparison between the European Union and the United States
C. Iglesias-Lopez et al.
CRITICAL REVIEWS IN TOXICOLOGY (2019)
Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare
Bengt Jonsson et al.
EUROPEAN JOURNAL OF HEALTH ECONOMICS (2019)
Building a Program Implications for infrastructure, nursing education, and training for CAR T-cell therapy
Lenise Taylor et al.
CLINICAL JOURNAL OF ONCOLOGY NURSING (2019)
Assessing the Financial Value of Patient Engagement: A Quantitative Approach from CTTI's Patient Groups and Clinical Trials Project
Bennett Levitan et al.
THERAPEUTIC INNOVATION & REGULATORY SCIENCE (2018)
Enhancing patient-level clinical data access to promote evidence-based practice and incentivize therapeutic innovation
Alice Fortunato et al.
ADVANCED DRUG DELIVERY REVIEWS (2018)
The impact of parallel regulatory-health technology assessment scientific advice on clinical development. Assessing the uptake of regulatory and health technology assessment recommendations
Giovanni Tafuri et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Evolving Industry Partnerships and Investments in Cell and Gene Therapies (vol 22, pg 623, 2018)
Devyn M. Smith et al.
CELL STEM CELL (2018)
Funding breakthrough therapies: A systematic review and recommendation
E. Hanna et al.
HEALTH POLICY (2018)
Registry Contributions to Strengthen Cell and Gene Therapeutic Evidence
Mohamed Abou-El-Enein et al.
MOLECULAR THERAPY (2018)
Gene therapy: evidence, value and affordability in the US health care system
Grace Hampson et al.
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH (2018)
Evolution of Business Models in Regenerative Medicine: Effects of a Disruptive Innovation on the Innovation Ecosystem
Geoffrey Banda et al.
CLINICAL THERAPEUTICS (2018)
From scientific discovery to treatments for rare diseases - the view from the National Center for Advancing Translational Sciences - Office of Rare Diseases Research
Petra Kaufmann et al.
ORPHANET JOURNAL OF RARE DISEASES (2018)
Overcoming barriers to facilitate the regulation of multi-centre regenerative medicine clinical trials
Erika Kleiderman et al.
STEM CELL RESEARCH & THERAPY (2018)
Challenges in Advanced Therapy Medicinal Product Development: A Survey among Companies in Europe
Renske M. T. ten Ham et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2018)
What does meaningful look like? A qualitative study of patient engagement at the Pan-Canadian Oncology Drug Review: perspectives of reviewers and payers
Linda Rozmovits et al.
JOURNAL OF HEALTH SERVICES RESEARCH & POLICY (2018)
Comprehensive analysis of the clinical immuno-oncology landscape
J. Tang et al.
ANNALS OF ONCOLOGY (2018)
Progress in Rare Diseases Research 2010-2016: An IRDiRC Perspective
Hugh J. S. Dawkins et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2018)
Characteristics of Preapproval and Postapproval Studies for Drugs Granted Accelerated Approval by the US Food and Drug Administration
Huseyin Naci et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Patient-Reported Outcome and Observer-Reported Outcome Assessment in Rare Disease Clinical Trials: An ISPOR COA Emerging Good Practices Task Force Report
Katy Benjamin et al.
VALUE IN HEALTH (2017)
Concise Review: The High Cost of High Tech Medicine: Planning Ahead for Market Access
Dawn Driscoll et al.
STEM CELLS TRANSLATIONAL MEDICINE (2017)
A quantitative, multi-national and multi-stakeholder assessment of barriers to the adoption of cell therapies
Benjamin M. Davies et al.
JOURNAL OF TISSUE ENGINEERING (2017)
More Haste, Less Speed: Could Public-Private Partnerships Advance Cellular immunotherapies?
Tania Bubela et al.
FRONTIERS IN MEDICINE (2017)
Affordable orphan drugs: a role for not-for-profit organizations
Elin H. Davies et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2017)
The path to successful commercialization of cell and gene therapies: empowering patient advocates
Gerhard Bauer et al.
CYTOTHERAPY (2017)
How aligned are the perspectives of EU regulators and HTA bodies? A comparative analysis of regulatory-HTA parallel scientific advice
Giovanni Tafuri et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Overcoming Challenges Facing Advanced Therapies in the EU Market
Mohamed Abou-El-Enein et al.
CELL STEM CELL (2016)
Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways
Michael Ermisch et al.
Frontiers in Pharmacology (2016)
Does Conditional Approval for New Oncology Drugs in Europe Lead to Differences in Health Technology Assessment Decisions?
I. Lipska et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2015)
EVALUATION OF PATIENT INVOLVEMENT IN A HEALTH TECHNOLOGY ASSESSMENT
Mylene Tantchou Dipankui et al.
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2015)
REGULATORY WATCH Impact of scientific advice from the European Medicines Agency
Matthias P. Hofer et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Cell-based therapy technology classifications and translational challenges
Natalie M. Mount et al.
PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES (2015)
ADAPTIVE PATHWAYS MAY EXPAND THE GAP BETWEEN REGULATORS AND PAYERS
M. Toumi et al.
VALUE IN HEALTH (2015)
Untested, unproven, and unethical: the promotion and provision of autologous stem cell therapies in Australia
Alison K. McLean et al.
STEM CELL RESEARCH & THERAPY (2015)
Regulatory approval for autologous human cells and tissue products in the United States, the European Union, and Japan
Kazuo Yano et al.
REGENERATIVE THERAPY (2015)
IDENTIFICATION AND REVIEW OF COST-EFFECTIVENESS MODEL PARAMETERS: A QUALITATIVE STUDY
Eva Kaltenthaler et al.
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2014)
US Food and Drug Administration international collaborations for cellular therapy product regulation
Judith A. Arcidiacono et al.
STEM CELL RESEARCH & THERAPY (2012)
分享论文
